Cancer Research UK tests first of its kind vaccine to treat lung cancer

A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc. Cancer Research UK will manage the initial clinical development of AST-VAC2, a promising immunotherapy candidate derived from a standardised human embryonic stem cell line, which was brought to the charity through its Clinical Development Partnerships (CDP) scheme. If shown to be safe and effective, it’s hoped that AST-VAC2 could be used as an additional treatment for patients who no longer have advanced disease but whose lung cancer